Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Helmut Butzkueven

Showing results (271-280 of 390) with videos related to

Pageof 39
Sort By:
Quality of Life Research : an International Journal of Quality of Life Aspects of Treatment, Care and Rehabilitation|August 31, 2025
The relationship between patient-reported quality of life and clinician-rated outcome scores in patients with autoimmune encephalitis: a study of the Australian Autoimmune Encephalitis ConsortiumChristina Kazzi, Nabil Seery, Sarah Griffith, et al.
Journal of Neuroinflammation|May 20, 2026
Plasma proteome in LGI-1 autoimmune encephalitisRobb Wesselingh, Nabil Seery, Katherine Ko, et al.
Transplantation and Cellular Therapy|March 9, 2026
A computerised cognitive test for immune effector cell-associated neurotoxicity syndrome in chimeric antigen receptor T-cell therapy recipients: a pilot studyChristina Kazzi, David Darby, Miriam Wronski, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|November 26, 2022
Comparative effectiveness of cladribine tablets versus other oral disease-modifying treatments for multiple sclerosis: Results from MSBase registryTim Spelman, Serkan Ozakbas, Raed Alroughani, et al.
Plos One|November 8, 2012
Geographical variations in sex ratio trends over time in multiple sclerosisMaria Trojano, Guglielmo Lucchese, Giusi Graziano, et al.
Transplantation and Cellular Therapy|November 28, 2025
Repeatable Battery for the Assessment of Neuropsychological Status: Preliminary Utility for Subacute Cognitive Monitoring after Immune Effector Cell-Associated Neurotoxicity Syndrome after Chimeric Antigen Receptor T-Cell TherapyChristina Kazzi, Sarah P Griffith, Katherine Y Ko, et al.
Brain : a Journal of Neurology|December 12, 2023
Vitamin D did not reduce multiple sclerosis disease activity after a clinically isolated syndromeHelmut Butzkueven, Anne-Louise Ponsonby, Mark S Stein, et al.
Journal of the Neurological Sciences|April 18, 2012
Increasing age at disability milestones among MS patients in the MSBase RegistryIlya Kister, Eric Chamot, Gary Cutter, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|October 19, 2022
Comparing switch to ocrelizumab, cladribine or natalizumab after fingolimod treatment cessation in multiple sclerosisChao Zhu, Zhen Zhou, Izanne Roos, et al.
Neurodegenerative Disease Management|June 8, 2023
A plain language summary on the effectiveness of cladribine tablets compared with other oral treatments for multiple sclerosis: results from the MSBase registryTim Spelman, Serkan Ozakbas, Raed Alroughani, et al.
Pageof 39

Showing results (271-280 of 390) with videos related to

Sort By:
Pageof 39
Quality of Life Research : an International Journal of Quality of Life Aspects of Treatment, Care and Rehabilitation|August 31, 2025
The relationship between patient-reported quality of life and clinician-rated outcome scores in patients with autoimmune encephalitis: a study of the Australian Autoimmune Encephalitis ConsortiumChristina Kazzi, Nabil Seery, Sarah Griffith, et al.
Journal of Neuroinflammation|May 20, 2026
Plasma proteome in LGI-1 autoimmune encephalitisRobb Wesselingh, Nabil Seery, Katherine Ko, et al.
Transplantation and Cellular Therapy|March 9, 2026
A computerised cognitive test for immune effector cell-associated neurotoxicity syndrome in chimeric antigen receptor T-cell therapy recipients: a pilot studyChristina Kazzi, David Darby, Miriam Wronski, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|November 26, 2022
Comparative effectiveness of cladribine tablets versus other oral disease-modifying treatments for multiple sclerosis: Results from MSBase registryTim Spelman, Serkan Ozakbas, Raed Alroughani, et al.
Plos One|November 8, 2012
Geographical variations in sex ratio trends over time in multiple sclerosisMaria Trojano, Guglielmo Lucchese, Giusi Graziano, et al.
Transplantation and Cellular Therapy|November 28, 2025
Repeatable Battery for the Assessment of Neuropsychological Status: Preliminary Utility for Subacute Cognitive Monitoring after Immune Effector Cell-Associated Neurotoxicity Syndrome after Chimeric Antigen Receptor T-Cell TherapyChristina Kazzi, Sarah P Griffith, Katherine Y Ko, et al.
Brain : a Journal of Neurology|December 12, 2023
Vitamin D did not reduce multiple sclerosis disease activity after a clinically isolated syndromeHelmut Butzkueven, Anne-Louise Ponsonby, Mark S Stein, et al.
Journal of the Neurological Sciences|April 18, 2012
Increasing age at disability milestones among MS patients in the MSBase RegistryIlya Kister, Eric Chamot, Gary Cutter, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|October 19, 2022
Comparing switch to ocrelizumab, cladribine or natalizumab after fingolimod treatment cessation in multiple sclerosisChao Zhu, Zhen Zhou, Izanne Roos, et al.
Neurodegenerative Disease Management|June 8, 2023
A plain language summary on the effectiveness of cladribine tablets compared with other oral treatments for multiple sclerosis: results from the MSBase registryTim Spelman, Serkan Ozakbas, Raed Alroughani, et al.
Pageof 39